Prestige Biopharma Limited is an innovative biopharmaceutical company specialising in the development and manufacturing of cutting-edge antibody-based drugs and biosimilars. With an emphasis on research and innovation, the company is on track to secure EMA approval for its first biosimilar product, Tuznue, in September 2024, which is available for partnership. Additionally, Prestige Biopharma’s innovative pipeline features a monoclonal antibody targeting pancreatic cancer that is currently undergoing clinical trials, showcasing the company’s commitment to tackling significant health challenges.

Services include:
– Anatomical Therapeutic Chemical (ATC) Classification
– Biologics
– Development of antibody-based drugs
– Manufacturing of biosimilars
– Clinical trial support for monoclonal antibodies

Prestige Biopharma Limited continues to advance in the biopharmaceutical sector, dedicated to delivering top-tier solutions to the pharmaceutical industry. For further information, please visit prestigebiopharma.com.